Home
|
Inbox
|
Search
|
View Abstract
Treatment of Malignant Mesothelioma Using Novel Potent Radiosensitizer Sulfoquinovosylacylpropandiol
Description
.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px } .abstract { overflow-x:scroll } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px } .abstract td, th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; } .abstract a { overflow-wrap: break-word; word-wrap: break-word; }
A2689 - Treatment of Malignant Mesothelioma Using Novel Potent Radiosensitizer Sulfoquinovosylacylpropandiol
Author Block: E. Inamasu; Nagasaki University Hospital, Nagasaki, Japan.
Malignant pleural mesothelioma is a refractory disease, and curability is low even with Trimodarity therapy combined with surgery, chemotherapy, and radiation therapy. Asbestos exposure is one cause and is expected to increase in the future.
Sulfoquinovosyl-acyl propanediol (SQAP), which is almost harmless to living bodies, tends to accumulate in tumor cells in vivo, leading to temporary reoxygenation of solid cancer tissue, It is clear that synergistic.
In the mouse model subcutaneously transplanted with prostate cancer, the radiation sensitization effect by SQAP was observed (Y. Sawada, et al. International Journal Of Urology 2015; right figure).
In this experiment, we will demonstrate by mouse model that radiation therapy effect on human pleural malignant mesothelioma will be enhanced by administering SQAP, and I would like to demonstrate the path to clinical application as a new treatment option.
We used two human malignant pleural mesothelioma cell lines, MSTO-211 H (biphasic) and MESO-4 (epithelial). These were transplanted subcutaneously into immunocompromised mice to prepare carrier mice model mice. On the other hand, we examined the tumor growth inhibitory effect of SQAP, and as a result, tumor growth was suppressed with a significant difference in the combination group of SQAP and radiation. On the other hand, in orthotopic model mice transplanted with a mesothelioma strain in the thoracic cavity, the survival period was prolonged by the combined use of SQAP and radiation.
SQAP could be a novel potent radiosensitizer in malignant pleural mesothelioma.
Author Block: E. Inamasu; Nagasaki University Hospital, Nagasaki, Japan.
Malignant pleural mesothelioma is a refractory disease, and curability is low even with Trimodarity therapy combined with surgery, chemotherapy, and radiation therapy. Asbestos exposure is one cause and is expected to increase in the future.
Sulfoquinovosyl-acyl propanediol (SQAP), which is almost harmless to living bodies, tends to accumulate in tumor cells in vivo, leading to temporary reoxygenation of solid cancer tissue, It is clear that synergistic.
In the mouse model subcutaneously transplanted with prostate cancer, the radiation sensitization effect by SQAP was observed (Y. Sawada, et al. International Journal Of Urology 2015; right figure).
In this experiment, we will demonstrate by mouse model that radiation therapy effect on human pleural malignant mesothelioma will be enhanced by administering SQAP, and I would like to demonstrate the path to clinical application as a new treatment option.
We used two human malignant pleural mesothelioma cell lines, MSTO-211 H (biphasic) and MESO-4 (epithelial). These were transplanted subcutaneously into immunocompromised mice to prepare carrier mice model mice. On the other hand, we examined the tumor growth inhibitory effect of SQAP, and as a result, tumor growth was suppressed with a significant difference in the combination group of SQAP and radiation. On the other hand, in orthotopic model mice transplanted with a mesothelioma strain in the thoracic cavity, the survival period was prolonged by the combined use of SQAP and radiation.
SQAP could be a novel potent radiosensitizer in malignant pleural mesothelioma.
|
Home
|
Inbox
|
Search
|